Objective. There is no evidence for a genetic association between organic anion transporters 1-3 (SLC22A6, SLC22A7, and SLC22A8) and multidrug resistance protein 4 (MRP4; encoded by ABCC4) with the levels of serum urate or gout. The M aori and Pacific (Polynesian) population of New Zealand has the highest prevalence of gout worldwide. The aim of this study was to determine whether any Polynesian population-specific genetic variants in SLC22A6-8 and ABCC4 are associated with gout.
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Objective. There is no evidence for a genetic association between organic anion transporters 1-3 (SLC22A6, SLC22A7, and SLC22A8) and multidrug resistance protein 4 (MRP4; encoded by ABCC4) with the levels of serum urate or gout. The M aori and Pacific (Polynesian) population of New Zealand has the highest prevalence of gout worldwide. The aim of this study was to determine whether any Polynesian population-specific genetic variants in SLC22A6-8 and ABCC4 are associated with gout.
Methods. All participants had ‡3 self-reported M aori and/or Pacific grandparents. Among the total sample set of 1,808 participants, 191 hyperuricemic and 202 normouricemic individuals were resequenced over the 4 genes, and the remaining 1,415 individuals were used for replication. Regression analyses were performed, adjusting for age, sex, and Polynesian ancestry. To study the functional effect of nonsynonymous variants of ABCC4, transport assays were performed in Xenopus laevis oocytes.
Results. A total of 39 common variants were detected, with an ABCC4 variant (rs4148500) significantly associated with hyperuricemia and gout. This variant was monomorphic for the urate-lowering allele in Europeans. There was evidence for an association of rs4148500 with gout in the resequenced samples (odds ratio . A rare population-specific allele (P1036L) with predicted strong functional consequence reduced the uric acid transport activity of ABCC4 by 30%.
Conclusion. An association between ABCC4 and gout and fractional excretion of uric acid is consistent with the established role of MRP4 as a unidirectional renal uric acid efflux pump.
Gout is a form of arthritis caused by an innate immune system reaction to monosodium urate crystals in patients with hyperuricemia (1). Gout is 3-4-fold more prevalent in men than in women (2) . Genome-wide association studies have identified genetic variants in loci encoding renal and intestinal uric acid transporters and associated accessory molecules (SLC2A9/GLUT9, ABCG2, SLC22A11/OAT4, SLC22A12/URAT1, SLC17A1/ NPT1, and PDZK1) that control serum urate levels in Europeans (3) (4) (5) . Most of these variants are associated with serum urate and gout in other ancestral groups (6, 7) . However, there remain other known uric acid transporters (SLC22A6-8/OAT1-3, ABCC4/MPR4) (8-12) without evidence at a genome-wide level of significance for genetic control of urate levels and the risk of gout (13) . Identifying natural common genetic variants that are associated with urate levels and the risk of gout in the genes encoding these molecules would both increase the understanding of the molecular basis of hyperuricemia and gout and highlight the molecules as targets for urate-lowering drugs. For example, small molecules reverse the urate-raising property of the common ATP-binding cassette subfamily G member 2 (ABCG2) 141K variant (14) , and lesinurad is a recently developed drug that promotes uric acid excretion via urate transporter 1 (15, 16) .
We hypothesized that the genome of the M aori and Pacific (Polynesian) population of New Zealand could contain genetic variants in SLC22A6-8 and ABCC4 (which are absent in Europeans) that control serum urate levels. This population group has the highest prevalence of gout worldwide (2), driven by inherent hyperuricemia (17, 18) . Furthermore, individuals of Polynesian ancestry exhibit lower urinary fractional excretion of uric acid (19) (20) (21) . Therefore, these genes were resequenced in 191 Polynesian individuals with the highest serum urate levels and 202 with the lowest serum urate levels, with the aim of detecting population-specific genetic variants that are associated with gout.
PATIENTS AND METHODS
Participants. All 1,808 Polynesian gout patients and controls in this study were drawn from the New Zealand M aori and Pacific Island populations and were recruited during the years 2006 to 2013 from within New Zealand. Only individuals with $3 self-reported Polynesian grandparents were included (Table 1) . Patients with gout fulfilled the 1977 American College of Rheumatology preliminary criteria for the classification of primary gout, as determined by clinical examination (22) . Participants who self-reported no history of gout were categorized as non-gout. From this group, 191 individuals with the highest serum urate levels (average 0.539 mmoles/liter in men and 0.511 mmoles/liter in women) and 202 individuals with the lowest serum urate levels (average 0.330 mmoles/liter in men and 0.284 mmoles/liter in women) were selected for resequencing (resequence sample set [n 5 393]). Of the remaining 1,415 subjects, 1,075 comprised the replication 1 sample set. The Lower South Ethics Committee (OTA/99/11/098) and New Zealand Multi-region Ethics Committee (MEC/05/10/130) granted ethics approval for analysis of these individuals.
A separate sample set (replication 2) comprised 181 individuals with gout and 159 without gout (non-gout), as ascertained using the above criteria. These participants were recruited in collaboration with Ng ati Porou Hauora Charitable Trust (NPHCT), the M aori iwi (tribe) health service provider located in the East Coast (Tair awhiti) region of the North Island of New Zealand. This separate sample set is comprised nearly exclusively (99.5%) of persons of New Zealand M aori (Eastern Polynesian) ancestry. The NPHCT study was approved by the Ng ati Porou Hauora Board, and ethics approval was granted by the Northern Y Region Health Research Ethics Committee (NTY07/07/074).
Urate and creatinine levels for all sample sets were obtained using serum and a spot urine sample (nonfasting), with sampling occurring at convenient times. Serum urate values at the time of recruitment are shown for all participants in Table 1 . Fractional excretion of uric acid was calculated using the Simkin index (23). Hyperuricemia was defined as $6 mg/dl in women and $7 mg/dl in men. The characteristics of the participants are shown in Table 1 .
Resequencing. Illumina-indexed libraries were constructed using 250 ng of native genomic DNA according to the manufacturer's protocol (Illumina), with the following modifications: 1) DNA was fragmented, using a Covaris E220 DNA sonicator, to range in size between 100 bp and 400 bp; 2) Illumina adapter-ligated library fragments were amplified for 8 cycles; 3) solid-phase reversible immobilization bead cleanup was used for enzymatic purification throughout the library process, as well as final library size selection targeting 300-500-bp fragments. Hybridization was performed with a custom version of a Roche NimbleGen SeqCap kit, according to the manufacturer's protocol. Ninety dual-indexed samples were combined and captured as a pool and run on a lane of Illumina HiSeq 2000, which produces ;36 Gb/lane of sequence. The total target capture was 2.59 Mb of genomic space that included the SLC22A6-8 and ABCC4 Using Genome Analysis Toolkit (GATK) best practice recommendations (24) , FASTQ files were aligned to the human decoy reference genome (build GRCh37) using BurrowsWheeler Aligner (BWA version 0.7.12 r1039) (25) . Resulting BAM files were processed using Picard (version 1.114) to mark reads that originate from duplication by polymerase chain reaction. This was followed by Indel Realignment and base recalibration using GATK version 3.3.0 (26) . GNU Parallel (version 20140422) (27) and GATK HaplotypeCaller (28) were used to generate genomic variant call files (GVCFs). These files were merged in batches of 100 using the GATK Merge GVCF command, followed by variant calling using the GATK Genotype GVCF command. The single-nucleotide polymorphisms (SNPs) in the resulting VCF were processed using the GATK variant quality score recalibration utility, taking quality by depth, Fisher score, mapping quality rank sum, and read position rank sum into account. This recalibration was applied to the VCF file, and SNPs with a truth sensitivity of ,99.00 were removed.
Each variant was annotated using Plink/Seq (version 0.10) (https://atgu.mgh.harvard.edu/plinkseq/), and for those variants found within the boundary of a gene or genes, the variants were classified as follows: intronic, exonic-unknown, exonic-missense, exonic-silent, 3
0 -UTR, and 5 0 -UTR. Rare variants were additionally annotated (see Supplementary  Table 2 , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/art.40110/abstract) with Combined Annotation Dependent Depletion (CADD) scores (29) using Gemini (version 0.12.2) (30).
Genotyping. All samples, including those in the resequencing experiment, were genotyped using either a TaqMan rs4148500 assay or a custom TaqMan Genotyping Assay (for chromosome 13:95724019) on a Roche LightCycler 480 instrument. The genotypes were autocalled by the LightCycler 480 software, and the reported dye signal plots were visually inspected for correct genotype clustering. There was 100% concordance between genotypes determined by TaqMan assay and genotypes obtained from the resequencing VCF files. No individual or combined sample set departed from Hardy-Weinberg equilibrium (P . 0.05).
Association analysis. Logistic regression was performed on the resequence data using Plink/Seq, with hyperuricemia as outcome. This model was adjusted for age and sex. Association with gout was tested by logistic regression with adjustment for age, sex, self-reported number of Polynesian grandparents, and Polynesian ancestral group (Western, Eastern, mixed) in the resequence, replication, and combined sample sets using R version 3.2.0 (31). Linear regression, with the same adjustors, was used to test for association with fractional excretion of uric acid and serum urate.
ATP-binding cassette subfamily C member 4 (ABCC4) functional assay. To study the effect of the rare allele of the P1036L coding SNP on the transport function of ABCC4, the relevant point mutant was first generated using site-directed mutagenesis (QuikChange; Stratagene) of Xenopus laevis expression constructs in the pGEMHE vector. Point mutants were also generated for 2 additional nonsynonymous variants, G187W and G487E, which showed reduced function in a previous study (32) . In each case, the fidelity of mutagenesis was assessed by sequencing the entire open reading frame. The transport function of wild-type and mutant ABCC4 was then assessed using [ 14 C] efflux in individual X laevis oocytes, as previously described for ABCG2 (12, 33) .
Collagenase-digested oocytes were thus microinjected with in vitro-transcribed complementary RNA (cRNA) (25 ng/ oocyte) for each construct, followed by transport assays after 2 days in culture. For [ 14 C]-urate efflux studies, oocytes were preinjected with 50 nl of 1,500 mM [ 14 C]-urate dissolved in efflux medium (ND96, pH 7.4). Pre-injected oocytes were then incubated in ND96 medium for 30 minutes at 168C for recovery. After incubation, the oocytes were washed in ND96 medium 4 times to remove any external adhering [ 14 C]-urate from the oocytes and were then subjected to efflux for 1 hour at room temperature (;258C) in ND96 medium (pH 7.4) in the absence or presence of drug; pharmacologic sensitivity was determined for tranilast, benzbromarone, and probenecid. Oocytes were then washed again 3 times with the ice-cold uptake medium to remove external radioisotope. The radioisotope content of each oocyte was measured using a scintillation counter after solubilization in 0.3 ml of 10% (volume/volume) sodium dodecyl sulfate (SDS) and the addition of 2.5 ml of scintillation fluid. The experiments included either 12-15 oocytes per group or 30 oocytes per group. Given the modest functional effects of coding mutations in ABCC4, we utilized twice the usual number of oocytes in this experiment. The radioisotope content of each oocyte was measured using a scintillation counter after solubilization in 0.3 ml of 10% (v/v) SDS and the addition of 2.5 ml of scintillation fluid. Statistical significance for individual experiments was defined as a 2-tailed P value of ,0.05 by Mann-Whitney rank sum test. Results are reported as the mean 6 SE.
ABCC4 Western blot analysis. Total cellular protein for Western blot analysis was prepared from groups of ;50 X laevis oocytes injected with relevant cRNAs that were transcribed in vitro from related constructs. After 48 hours of expression of protein from the injected cRNA, oocytes were transferred to 1.7-ml polypropylene microfuge tubes on ice and lysed using a Teflon homogenizer in lysis buffer (50 mM Tris HCl, pH 7.5, 50 mM NaCl, 1 mM EDTA, pH 8, 1% Triton X-100) supplemented with protease inhibitor cocktail (Roche). After clearing the lysate off yolk and cellular debris by centrifugation at 5,000 revolutions per minute for 10 minutes, the supernatant was stored at 2808C. Western blotting was performed using affinitypurified rabbit anti-ABCC4 polyclonal antibody (Cell Signaling Technology) at a titer of 1:1,000. Total lysates of proteins were fractionated using 7.5% SDS-polyacrylamide gel electrophoresis (Bio-Rad). Proteins were transferred to polyvinylidene difluoride membrane (Bio-Rad) at 100V for 3 hours. The membrane was blocked in 5% nonfat dry milk in Tris buffered saline-Tween 20 (TBST). Primary antibodies were diluted in 5% milk in TBST and incubated with the membrane at room temperature for 2 hours with continuous gentle shaking. Blots were washed in TBST and probed with a horseradish peroxidase-conjugated secondary antibody (Bio-Rad) in TBST containing 5% fat-free milk for 1 hour at room temperature. The membrane was then washed 4 times with TBST, and chemiluminescence was determined using an enhanced chemiluminescence technique (Pierce), following standard protocols.
RESULTS
Identification of common variants. A total of 39 variants with a frequency of .0.05 were detected by resequencing across the 4 loci, with the majority (n 5 26) in ABCC4 ( Table 2 ). All variants were tested for association with hyperuricemia, and 6 variants in ABCC4 were significantly associated (2 were in complete linkage disequilibrium) ( Table 2) . Accounting for variants in strong linkage disequilibrium (r 2 . 0.90), a total of 32 tests were performed (Table 2 and Figure 1) . Therefore, the corrected P value for significant association with hyperuricemia was P , 1.46 3 10
23
, which only rs4148500 achieved (odds ratio [OR] 1.86, P 5 6 3 10
24
). This variant was monomorphic for the urate-lowering allele in Europeans ( Table 2) .
Replication of rs4148500. Variant rs4148500 was genotyped over the replication 1 and replication 2 sample sets and tested for an association with gout (Table 3) . Gout rather than hyperuricemia was examined for the pragmatic reason that we had access to a large number of clinically ascertained gout patients for whom hyperuricemia could be assumed. Given the differences in allele frequency at ABCG2 rs2231142 between Western (Samoa, Tonga, Niue, Tokelau) and Eastern (New Zealand and Cook Island M aori) Polynesians (34), the non-gout samples were first subdivided into Eastern and Western Polynesians. The A allele frequency was 0.186 in Eastern Polynesians and 0.314 in Western Polynesians. Therefore, subsequent regression analyses were performed with additional adjustment for Eastern versus Western versus mixed ancestry in order to account for any intra-Polynesian stratification. Applying the ancestry adjustment (in addition to the number of Polynesian grandparents) to the resequence data set showed evidence for association of rs4148500 with both gout (Table 3 ) (OR 1.62, P 5 0.012) and hyperuricemia (OR 1.80, P 5 0.003).
The association with gout was replicated in the combined replication sample sets (replication 1 1 2) (OR 1.25, P 5 0.033), with significant association in replication 1 (OR 1.36, P 5 0.008) but not replication 2 (OR 0.80, P 5 0.36).
The minor allele of rs4148500 was also associated with an increased risk of gout in the combined resequence and replication sample sets (OR 1.30, P 5 0.004). Using the combined resequence and replication 1 and 2 sample sets, sexstratified sample sets were generated, revealing that the association was restricted to men (OR 1.43 [P 5 0.001] versus OR 0.98 [P 5 0.89] in women) ( Table 3) . Combining the male and female sample sets by meta-analysis demonstrated evidence for a differential strength of effect (P for heterogeneity 5 0.062, using a fixed-effects model). The effect size was similar between Western and Eastern Polynesian men (OR 1.41 [P 5 0.03] and OR 1.45 [P 5 0.02], respectively).
Association of rs4148500 with fractional excretion of uric acid. In the combined sample set, rs4148500 was tested for association with fractional excretion of uric Table 2 ) in resequenced samples across ABCC4, SLC22A6, SLC22A7, and SLC22A8.
acid in combined gout patients and non-gout controls and with serum urate in controls (Table 4) Table 4 ).
Identification of rare variants ABCC4 P1036L. Eighty rare variants were also detected in the resequenced Polynesian samples. These included 37 singleton variants (17 of which were not reported in 1000 Genomes), 19 variants with a prevalence of ,1% in controls (5 not reported in 1000 Genomes), and 24 with a prevalence of 1-5% in controls (3 not reported in 1000 Genomes) (see Supplementary Table 2, available ‡ Odds ratio (OR) 1.31, P 5 0.01 by meta-analysis combining the replication 1 and replication 2 sample sets using a fixed-effects model, and OR 1.15, P 5 0.59 using a random-effects model (P for heterogeneity [P het ] 5 0.048). § OR 1.42, P 5 1 3 10 24 by meta-analysis combining the resequence and replication 1 and replication 2 sample sets using a fixed-effects model, and OR 1.36, P 5 0.098 using a random-effects model (P het 5 0.036).
¶ OR 1.43, P 5 0.0015 by meta-analysis combining WP and EP men using a fixed-effects model, and OR 1.43, P 5 0.0015 using a random-effects model (P het 50.90). # OR 0.94, P 5 0.73 by meta-analysis combining WP and EP women using a fixed-effects model, and OR 0.99, P 5 0.97 using a random-effects model (P het 50.18). (Figure 2 ). ABCC4 exported uric acid at an ;2-fold slower rate compared with ABCG2 (ref. 33 and data not shown). Unlike ABCG2 (33), ABCC4 was sensitive to tranilast and benzbromarone, in addition to 1.0 mM probenecid (Figure 2A) . The presence of a leucine residue at position 1036 led to an ;35% reduction in uric acid efflux compared with wildtype but had no effect on protein expression ( Figure 2B) .
In contrast to a prior study of coding SNP effects in ABCC4 (32), we observed that the G487E coding SNP mutation did not affect ABCC4 function, whereas the G187W mutant had reduced function, as reported previously ( Figure 2B ). Additionally, unlike in the previous study (32) , in which reduced protein expression for the G187W mutant was observed, this mutant was fully expressed in oocytes, as shown by Western blotting. This discrepancy is perhaps a reflection of the different expression systems used (transient transfection of HEK 293 cells versus direct microinjection of cRNA in X laevis oocytes). A recent study in which transient transfection of HEK 293T cells was used also demonstrated normal expression of the 187W mutant (35) .
DISCUSSION
We used a resequencing approach to detect an association between ABCC4, which encodes multidrug resistance protein 4 (MRP4), and hyperuricemia (OR 1.80, P 5 0.003) and gout (OR 1.62, P 5 0.012) in a sample set from the New Zealand M aori and Pacific population. The association with gout was replicated (OR 1.25, P 5 0.033). These results demonstrate the utility of resequencing approaches in populations with a higher prevalence of the phenotype of interest in order to increase understanding of the molecular basis of disease. The reason for nonreplication of the association of rs4148500 with gout in the replication 2 sample set could be low power: there was only 43% power to detect an effect at a 5 0.05 and (based on data for the replication 1 sample set) an OR 1.36 and a minor allele frequency of 0.244. Nevertheless, the direction of effect in men in the replication sample set (OR 1.23, P . 0.05) was consistent with findings in the combined data whereby the minor A allele of rs4148500 confers risk of gout in male individuals of Polynesian ancestry.
Similarly, the gout risk allele was associated with reduced fractional excretion of uric acid in men (Table 4) . This finding is also important, because it provides further confirmation of MRP4 as a unidirectional efflux pump for uric acid (11, 12) . In avian proximal tubule epithelium, MRP4 is the dominant apical secretory uric acid transporter, and ABCG2 apparently does not significantly contribute to uric acid secretion in the avian system (36) . Interestingly, in this system, uric acid secretion is inhibited by AMP-activated protein kinase. The gene encoding the gamma-2 subunit of AMP-activated protein kinase is associated with the urate concentration and gout in European individuals (5, 7) . MRP4 also has been proposed as a transporter for urate excretion into the circulation because of its basolateral expression in the liver (11) . It has been demonstrated that furosemide and thiazide diuretics and the urate-lowering benzbromarone inhibit, whereas the active metabolite of the urate-lowering allopurinol (oxypurinol) stimulates, MRP4-mediated renal uric acid efflux (37) . Consistent with this, we observed that ABCC4 was sensitive to benzbromarone and probenecid at a higher concentration (1.0 mM). Thus, MRP4 may emerge as being a clinically important transporter in the management of gout and comorbid conditions.
The association of ABCC4 with gout and fractional excretion of uric acid was restricted to male individuals (Tables 3 and 4 ). This finding may be of particular clinical relevance considering the very high rates of gout in M aori and Pacific men; gout affects .25% of M aori and Pacific men older than age 60 years (2) . The differential effects of an association of genetic variants with urate and gout between men and women represent a phenomenon observed at some other uric acid transporter loci. At ABCG2, an association of rs2231142 with gout was weaker in women (OR 1.5) than in men (OR 2.0), which at least partly reflects a 50% greater effect of rs2231142 on serum urate levels in men (5) . At SLC2A9, there is a 70% greater effect on serum urate levels in women than in men, while the effect on gout is similar in women and men (5) . At SLC17A1/NPT1, SLC22A11/OAT4, and SLC22A12/ URAT1, however, although the effect sizes are up to onethird larger in men, any sex-specific effects remain to be established and are not of the extent observed at SLC2A9, ABCG2, and ABCC4. Understanding the molecular basis of the interaction between sex and genotype at these loci will illuminate the molecular mechanisms of control of urate levels.
The rare (;1%) Western Polynesian-specific 1036L variant selected for follow-up genotyping was not significantly associated with gout in the combined resequence and replication 1 and 2 sample sets (P 5 0.15), although the direction of effect (OR 3.1) was consistent with overrepresentation of the 1036L variant in resequenced individuals with hyperuricemia (n 5 7) compared with none in normouricemic individuals. This variant also had an extremely high CADD score, predicting a pathogenic (functional) effect. Consistent with the extremely high CADD score and with overrepresentation of the 1036L allele in hyperuricemic individuals and those with gout, the 1036L allele reduced uric acid reflux from X laevis oocytes by 30%. It can be predicted that individuals with this allele filter less uric acid into the urine. Residue 1036 is intracellular, being located in the second nucleotide-binding domain (32) . ABCC4 is a highly polymorphic gene; for example, .400 missense variants were reported in the Exome Aggregation Consortium database of 60,706 unrelated individuals (38) , although 1036L is not reported in this database. Some of the variants have been evaluated for an effect on the functional characteristics of MRP4 (e.g., contributing to intracellular accumulation of antiviral agents [32] and methylated arsenic metabolites [35] , and to lack of localization to the plasma membrane [35] ). With urate control and risk of gout as clinical outcomes, it will be necessary to systematically test missense variants of ABCC4 for association with urate concentrations and risk of gout, and to evaluate their influence on the ability of MRP4 to transport uric acid.
In the current study, an extreme sample drawn from the hyperuricemic Polynesian population was resequenced based on the hypothesis that this population has a higher prevalence of urate-raising genetic variants in the selected genes (postulated to control urinary uric acid excretion) that had not previously been associated with urate levels or gout by genome-wide association studies. In the case of ABCC4, the minor risk allele (A) of rs4148500 was not present in Europeans yet had a prevalence of 24% in persons of Polynesian descent. Thus, rs4148500 is a population-specific variant that highlights the relative importance of genetic variation in ABCC4 as a risk factor for gout in the population of New Zealand M aori and Pacific men. Determining whether rs4148500 is the causal variant at the ABCC4 locus will require sequence information from the entire region in the Polynesian genome and genotyping of variants in linkage disequilibrium. Furthermore, risk allele A was also prevalent in the Asian population (19%) ( Table 2 ), which warrants testing for an association with gout in populations from this region, with a focus on replicating the male-specific effect observed in the Polynesian population of New Zealand.
